15.20 USD
↗ 0.26 (1.74%)AT CLOSE (03:59 PM EDT)
NovoCure Limited Ordinary Shares
NVCRNASDAQ • USD
15.12
↘ 0.08 (0.56%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
15.12
↘ 0.08 (0.56%)
Market: CLOSED
NVCR is currently priced at $15.21. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Oct 5, 2026.
Open?$14.83
High?$15.30
Low?$14.56
Prev. Close?$14.94
Volume?1.8M
Avg. Volume?1.1M
VWAP?$15.07
Rel. Volume?1.58x
Bid / Ask
Bid?$14.76 × 900
Ask?$15.37 × 700
Spread?$0.61
Midpoint?$15.07
Valuation & Ratios
Market Cap?1.8B
Shares Out?116.4M
Float?105.4M
Float %?90.5%
P/E Ratio?N/A
P/B Ratio?5.24
EPS?-$1.28
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Themes
Employees
1.6K
Market Cap
1.7B
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Website
Listed
2015-10-02
Address
NO. 4 THE FORUM
ST. HELIER,
Phone: 44 (0)15 3475 6700
ST. HELIER,
Phone: 44 (0)15 3475 6700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?8
Momentum?80
Short Sent.?23
Piotroski F-Score?4/9Mixed
Altman Z-Score?0.77Distress
Confidence?54%Low
Short InterestVery High
Short % of Float?11.20%High
Short Interest?11.8M
Days to Cover?11.5
Free Float105.4M
Avg Daily Volume1.0M
Settlement Date2026-09-15
Financial Health
Current Ratio?2.89Strong
Quick Ratio?2.70Strong
Cash Ratio?0.42Low
Debt/Equity?0.58Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score92/100
P/E?N/A▾
P/B?5.24FAIR▾
Peers100
S&P35
P/S?2.53CHEAP▾
Peers100
S&P57
P/FCF?N/A▾
EV/EBITDA?-13.6CHEAP▾
S&P97
EV/Sales?2.68CHEAP▾
Peers100
S&P65
Returns & Efficiency
ROE?-43.9%WEAK▾
S&P3
ROA?-18.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-25434000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day